British American Tobacco announces "Vuse One" after U turn on sale of unauthorized vapes

British American Tobacco is preparing to sell its first disposable vape in the U.S. reversing years of opposition to unauthorised devices amidst a booming $8 billion market for synthetic nicotine products.

The product, Vuse One is yet to receive approval from the U.S. Food and Drug Administration, but is set to join the market. 

Since July 2022, FDA rules require synthetic nicotine products to have agency approval. Many manufactures have ignored these rules resulting in a lucrative but illegal market.

BAT estimates U.S. single-use vape sales at $8 billion last year, around 70% of total industry sales.

The tobacco giant’s U-turn comes after years of lobbying lawmakers and pursuing court cases to block unauthorised disposable vapes, calling them a threat to consumers.

Now, the market for these products, often high in nicotine and appealing flavours, has exploded, causing BAT and rivals like Altria to reconsider their stance.

Luis Pinto, the company’s U.S. spokesman, said, “Not having access to this world weighs on our company's bottom line.”

The British company has publicly acknowledged the pressure of lost sales due to unregulated competitors, which has driven this sudden U-turn.

Rather than relying on FDA premarket authorisation, Pinto emphasises that BAT plans to enforce internal compliance measures, including age verification and controlled distribution, and avoid youth-oriented flavors and promotions. 

The FDA has stressed that marketing a product without premarket authorisation is unlawful. While BAT has a pending application for Vuse One, the agency has not granted a “legal safe harbour” for sales.

While FDA is meant to review applications within 180 days, delays have often stretched to years, leaving legal uncertainty and a booming grey market.

The company has cited the FDA’s use of “enforcement discretion” in other cases to justify its launch. 

Public health advocates and campaigners have sharply criticised BAT’s decision, warning that marketing and retailer safeguards cannot replace FDA premarket authorisation.

Critics, however, warn that such reliance on marketing and retail oversight cannot replace regulatory approval, and that public health risks, particularly for underage users, remain significant.

Brian King, executive vice president for U.S. tobacco control programmes at the Campaign for Tobacco-Free Kids, described the move as “illegal and dangerous,” highlighting the risks to minors and non-smokers.

Consumer groups and social media commentators have also voiced concern, accusing the global tobacco firm of prioritising profits over public safety.

Many point to the broader explosion of unregulated synthetic nicotine products in the U.S., which have drawn young users with flavours such as “rainbow bubblegum” and “cookie butter."

This trend suggests that permitting unauthorised sales, even under corporate oversight, could worsen health risks and normalise underage vaping.

Synthetic nicotine, produced in labs rather than extracted from tobacco, has allowed companies to sidestep existing regulations, though the FDA has clarified that premarket approval is still required.

Tobacco use is the leading preventable cause of disease and death in the U.S., responsible for around 480,000 deaths each year, mostly from cancer.

According to the CDC, around 2.5 million U.S. high school students reported using e-cigarettes in 2024, many favouring disposable devices with high nicotine concentrations and sweet flavours.

Copied